newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

- Studies show mechanism of action and biodistribution of GEM103 and support continued development as a potential treatment for AMD Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments